Improved Detection of New MS Lesions during Follow-Up Using an Automated MR Coregistration-Fusion Method

References

1. 1.↵
   2. Polman CH,
   3. Reingold SC,
   4. Banwell B, et al

   . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Thompson AJ,
   3. Banwell BL,
   4. Barkhof F, et al

   . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

   CrossRefPubMed
3. 3.↵
   2. Filippi M,
   3. Rocca MA,
   4. Ciccarelli O, et al

   ; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292–303 doi:10.1016/S1474-4422(15)00393-2 pmid:26822746

   CrossRefPubMed
4. 4.↵
   2. Wattjes MP,
   3. Rovira À,
   4. Miller D, et al

   ; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11:597–606 doi:10.1038/nrneurol.2015.157 pmid:26369511

   CrossRefPubMed
5. 5.↵
   2. Erbayat Altay E,
   3. Fisher E,
   4. Jones SE, et al

   . Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol 2013;70:338–44 doi:10.1001/2013.jamaneurol.211 pmid:23599930

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Barkhof F,
   3. Simon JH,
   4. Fazekas F, et al

   . MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2011;8:13–21 doi:10.1038/nrneurol.2011.190 pmid:22143362

   CrossRefPubMed
7. 7.↵
   2. Horsfield MA,
   3. Rocca MA,
   4. Pagani E, et al

   . Estimating brain lesion volume change in multiple sclerosis by subtraction of magnetic resonance images. J Neuroimaging 2016;26:395–402 doi:10.1111/jon.12344 pmid:27019077

   CrossRefPubMed
8. 8.↵
   2. Battaglini M,
   3. Rossi F,
   4. Grove RA, et al

   . Automated identification of brain new lesions in multiple sclerosis using subtraction images. J Magn Reson Imaging 2014;39:1543–49 doi:10.1002/jmri.24293 pmid:24987754

   CrossRefPubMed
9. 9.↵
   2. Ganiler O,
   3. Oliver A,
   4. Diez Y, et al

   . A subtraction pipeline for automatic detection of new appearing multiple sclerosis lesions in longitudinal studies. Neuroradiology 2014;56:363–74 doi:10.1007/s00234-014-1343-1 pmid:24590302

   CrossRefPubMed
10. 10.↵
    2. Sweeney EM,
    3. Shinohara RT,
    4. Shea CD, et al

    . Automatic lesion incidence estimation and detection in multiple sclerosis using multisequence longitudinal MRI. AJNR Am J Neuroradiol 2013;34:68–73 doi:10.3174/ajnr.A3172 pmid:22766673

    Abstract/FREE Full Text
11. 11.↵
    2. Patel N,
    3. Horsfield MA,
    4. Banahan C, et al

    . Detection of focal longitudinal changes in the brain by subtraction of MR images. AJNR Am J Neuroradiol 2017;38:923–27 doi:10.3174/ajnr.A5165 pmid:28364006

    Abstract/FREE Full Text
12. 12.↵
    2. van Heerden J,
    3. Rawlinson D,
    4. Zhang AM, et al

    . Improving multiple sclerosis plaque detection using a semiautomated assistive approach. AJNR Am J Neuroradiol 2015;36:1465–71 doi:10.3174/ajnr.A4375 pmid:26089318

    Abstract/FREE Full Text
13. 13.↵
    2. von Elm E,
    3. Altman DG,
    4. Egger M, et al

    ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573–77 doi:10.7326/0003-4819-147-8-200710160-00010 pmid:17938396

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444–52 doi:10.1212/WNL.33.11.1444 pmid:6685237

    Abstract/FREE Full Text
15. 15.↵
    2. Landis JR,
    3. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Cicchetti DV

    . Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994;6:284–90 doi:10.1037/1040-3590.6.4.284

    CrossRef
17. 17.↵
    R statistical and computing software. http://www.r-project.org/. Accessed March 1, 2015
18. 18.↵
    2. Bilello M,
    3. Arkuszewski M,
    4. Nasrallah I, et al

    . Multiple sclerosis lesions in the brain: computer assisted assessment of lesion load dynamics on 3D FLAIR MR images. Neuroradiol J 2012;25:17–21 doi:10.1177/197140091202500102 pmid:24028871

    CrossRefPubMed
19. 19.↵
    2. Tan IL,
    3. van Schijndel RA,
    4. Fazekas F, et al

    . Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study. J Neurol 2002;249:767–73 doi:10.1007/s00415-002-0712-6 pmid:12111312

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Wang W,
    3. van Heerden J,
    4. Tacey MA, et al

    . Neuroradiologists compared with non-neuroradiologists in the detection of new multiple sclerosis plaques. AJNR Am J Neuroradiol 2017;38:1323–27 doi:10.3174/ajnr.A5185 pmid:28473341

    Abstract/FREE Full Text
21. 21.↵
    2. Moraal B,
    3. Meier DS,
    4. Poppe PA, et al

    . Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology 2009;250:506–14 doi:10.1148/radiol.2501080480 pmid:19037018

    CrossRefPubMed
22. 22.↵
    2. Tan IL,
    3. van Schijndel RA,
    4. Pouwels PJ, et al

    . Serial isotropic three-dimensional fast FLAIR imaging: using image registration and subtraction to reveal active multiple sclerosis lesions. AJR Am J Roentgenol 2002;179:777–82 doi:10.2214/ajr.179.3.1790777 pmid:12185063

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Traboulsee A,
    3. Simon JH,
    4. Stone L, et al

    . Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 2016;37:394–401 doi:10.3174/ajnr.A4539 pmid:26564433

    Abstract/FREE Full Text
24. 24.↵
    2. Yu JP,
    3. Kansagra AP,
    4. Mongan J

    . The radiologist's workflow environment: evaluation of disruptors and potential implications. J Am Coll Radiol 2014;11:589–93 doi:10.1016/j.jacr.2013.12.026 pmid:24775910

    CrossRefPubMed
25. 25.↵
    2. Trojano M,
    3. Tintore M,
    4. Montalban X, et al

    . Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol 2017;13:105–18 doi:10.1038/nrneurol.2016.188 pmid:28084327

    CrossRefPubMed
26. 26.↵
    2. Sormani MP,
    3. Rio J,
    4. Tintorè M, et al

    . Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605–12 doi:10.1177/1352458512460605 pmid:23012253

    CrossRefPubMed
27. 27.↵
    2. Freedman MS,
    3. Selchen D,
    4. Arnold DL, et al

    ; Canadian Multiple Sclerosis Working Group. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40:307–23 doi:10.1017/S0317167100014244 pmid:23603165

    CrossRefPubMed
28. 28.↵
    2. Sormani MP,
    3. Gasperini C,
    4. Romeo M, et al

    ; MAGNIMS study group. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology 2016;87:134–40 doi:10.1212/WNL.0000000000002830 pmid:27306626

    Abstract/FREE Full Text
29. 29.↵
    2. Bevan CJ,
    3. Cree BA

    . Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014;71:269–70 doi:10.1001/jamaneurol.2013.5486 pmid:24395449

    CrossRefPubMed
30. 30.↵
    2. Cotton F,
    3. Weiner HL,
    4. Jolesz FA, et al

    . MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46 doi:10.1212/01.WNL.0000046587.83503.1E pmid:12601106

    Abstract/FREE Full Text
31. 31.↵
    2. Kanda T,
    3. Fukusato T,
    4. Matsuda M, et al

    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417

    CrossRefPubMed
32. 32.↵
    2. McNamara C,
    3. Sugrue G,
    4. Murray B, et al

    . Current and emerging therapies in multiple sclerosis: implications for the radiologist, Part 1: mechanisms, efficacy, and safety. AJNR Am J Neuroradiol 2017;38:1664–71 doi:10.3174/ajnr.A5147 pmid:28408630

    Abstract/FREE Full Text
33. 33.↵
    2. Vrenken H,
    3. Jenkinson M,
    4. Horsfield MA, et al

    ; MAGNIMS Study Group. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013;260:2458–71 doi:10.1007/s00415-012-6762-5 pmid:23263472

    CrossRefPubMed
34. 34.↵
    2. Moraal B,
    3. Wattjes MP,
    4. Geurts JJ, et al

    . Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 2010;255:154–63 doi:10.1148/radiol.09090814 pmid:20308453

    CrossRefPubMedWeb of Science